Frazier Life Sciences X, L.P. - 17 Sep 2025 Form 4 Insider Report for HilleVax, Inc. (HLVX)

Reporting relationship: 10%+ Owner
Issuer ticker: HLVX
Reported as of: 17 Sep 2025
Net transaction value: -$16,677,445
SEC form: 4
Accepted by SEC: 17 Sep 2025, 17:20:18 UTC
Prior SEC filing: 17 Sep 2024
Source filing: View source filing
Reporting owner signature: /s/ Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P.

Key filing fact

Frazier Life Sciences X, L.P. filed Form 4 for HilleVax, Inc. (HLVX) on 17 Sep 2025.

Key facts

This page summarizes Frazier Life Sciences X, L.P.'s Form 4 filing for HilleVax, Inc. (HLVX).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 17 Sep 2025, 17:20.

Change

Previous filing in this sequence was filed on 17 Sep 2024.
Current net transaction value: -$16,677,445.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (5)

CIK 0001790879 Primary reporting owner

Frazier Life Sciences X, L.P.

Relationship: 10%+ Owner
Address: FRAZIER LIFE SCIENCES MANAGEMENT, L.P., 1001 PAGE MILL RD, BUILDING 4, SUITE B, PALO ALTO
Signature: /s/ Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P.
Signature date: 17 Sep 2025

CIK 0001790880

FHMLS X, L.P.

Relationship: 10%+ Owner
Address: FRAZIER LIFE SCIENCES MANAGEMENT, L.P., 1001 PAGE MILL RD, BUILDING 4, SUITE B, PALO ALTO
Signature: /s/ Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P.
Signature date: 17 Sep 2025

CIK 0001790811

FHMLS X, L.L.C.

Relationship: 10%+ Owner
Address: FRAZIER LIFE SCIENCES MANAGEMENT, L.P., 1001 PAGE MILL RD, BUILDING 4, SUITE B, PALO ALTO
Signature: /s/ Steve R. Bailey, CFO of FHMLS X, L.L.C.
Signature date: 17 Sep 2025

CIK 0001341382

Topper James N

Relationship: 10%+ Owner
Address: FRAZIER LIFE SCIENCES MANAGEMENT, L.P., 1001 PAGE MILL RD, BUILDING 4, SUITE B, PALO ALTO
Signature: /s/ Steve R. Bailey, Attorney-in-Fact For Patrick J. Heron
Signature date: 17 Sep 2025

CIK 0001365617

Heron Patrick J

Relationship: Director, 10%+ Owner
Address: FRAZIER LIFE SCIENCES MANAGEMENT, L.P., 1001 PAGE MILL RD, BUILDING 4, SUITE B, PALO ALTO
Signature: /s/ Steve R. Bailey, Attorney-in-Fact For James N. Topper
Signature date: 17 Sep 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HLVX transaction

Common Stock

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value: $16,643,907
Shares: -8,535,337
Change %: -100%
Price: $1.95
Shares after: 0
Date: 17 Sep 2025
Ownership: By Frazier Life Sciences X, L.P.
Footnotes: F1, F2

HLVX transaction

Common Stock

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value: $33,538
Shares: -17,199
Change %: -100%
Price: $1.95
Shares after: 0
Date: 17 Sep 2025
Ownership: By Patrick J. Heron
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Frazier Life Sciences X, L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

Reflects disposition of the Issuer's equity securities upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 4, 2025, by and among Issuer, XOMA Royalty Corporation ("Parent") and XRA 4 Corp., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on September 17, 2025. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each share of the Issuer's Common Stock, par value $0.0001 per share ("Shares"), issued and outstanding immediately prior to the Effective Time was converted automatically into the right to receive (i) $1.95 in cash, without interest plus (ii) one non-transferable contractual contingent value right per Share.

Footnote F2

The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X,, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. James N. Topper and Patrick J. Heron are the sole managing members of FHMLS X, L.L.C. and share voting and investment power over the shares held by Frazier Life Sciences X, L.P. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

Footnote F3

Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding restricted stock unit ("RSU") immediately vested in full and was canceled in exchange for the right receive (a) an amount in cash, without interest, equal to the product obtained by multiplying (x) the $1.95 by (y) the number of shares underlying such RSU at the Effective Time and (b) one CVR for each share underlying such RSU.